Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
-
Kraig Labs (OTCQB: KBLB) was granted rights to a significant block of government-owned mulberry gardens located near its spider silk production operations
-
Pharming to participate in Oppenheimer Movers in Rare Disease Summit on Dec 11 in NYC. Chief Medical Officer Anurag Relan in fireside chat at 1:50 PM ET.
-
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an...
-
VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on...
-
Keiretsu MST hires Juan Arango to standardize diligence and syndication, driving faster, structured exits, syndication, IPO Angels, and other channels.
-
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"
-
Vertero appoints Jeffrey Kasten as Chief Business Officer to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative diseases.
-
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEOLaigo Bio’s SureTAC™ membrane protein degradation technology targets...
-
PARIS, 03 déc. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actionscomposant le capital socialNombre total de droits de...